Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 6, 2014, Pages 451-457

  Hartman, Lisa L R ^a,b   Crawford, John R ^b   Makale, Milan T ^a   Milburn, Mehrzad ^b   Joshi, Shweta ^a   Salazar, Andres M ^c   Hasenauer, Beth ^c   Vandenberg, Scott R ^a   Macdonald, Tobey J ^d   Durden, Donald L ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

pediatric gliomas; phase I II; poly ICLC; toll receptor; toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE;

ARTICLE; ATAXIA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DEHYDRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INJECTION SITE ERYTHEMA; KIDNEY DISEASE; LOW DRUG DOSE; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; MOTOR NEUROPATHY; NEUROECTODERM TUMOR; NEUROFIBROMATOSIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PONTINE GLIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOXYMETHYLCELLULOSE SODIUM; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; INFANT; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEOPLASM GRADING; POLY I-C; POLYLYSINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905124472     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000047     Document Type: Article

References (38)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
2. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision). Source: Central Brain Tumor Registry of the United States, Hinsdale, IL; 2012. Available at: Http://www.cbtrus.org.
3. Talmadge JE, Adams J, Phillips H, et al. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res. 1985;45:1058-1065.
4. Levy HB, Lvovsky E, Riley F, et al. Immune modulating effects of poly ICLC. Ann N Y Acad Sci. 1980;350:33-41.
5. Black PL, Hartmann D, Pennington R, et al. Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC]. Int J Immunopharmacol. 1992;14:1341-1353.
6. Levy HB. Historical overview of the use of polynucleotides in cancer. J Biol Response Mod. 1985;4:475-480.
7. Levy HB. Induction of interferon in vivo by polynucleotides. Tex Rep Biol Med. 1977;35:91-98.
8. Lampkin BC, Levine AS, Levy H, et al. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-Llysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: A report from the Children's Cancer Study Group. Cancer Res. 1985;45(Pt 2): 5904-5909.
9. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778-809.
10. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene. 1999;18:6112-6120.
11. Jakacki RI, Bouffet E, Adamson PC, et al. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: A Children's Oncology Group phase 1 consortium study. Neuro Oncol. 2011;13:910-915.
12. Zhu X, Nishimura F, Sasaki K, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10.
13. Johnson R, Wright KD, Gilbertson RJ. Molecular profiling of pediatric brain tumors: Insight into biology and treatment. Curr Oncol Rep. 2009;11:68-72.
14. Salazar AM, Levy HB, Ondra S, et al. Long-Term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: An open pilot study. Neurosurgery. 1996;38:1096-1103; discussion 1103-1094.
15. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ Tcell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29: 330-336.
16. Rosenfeld MR, Chamberlain MC, Grossman SA, et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010;12: 1071-1077.
17. Stephenson T. How children's responses to drugs differ from adults. Br J Clin Pharmacol. 2005;59:670-673.
18. Curran EK, Le GM, Sainani KL, et al. Do children and adults differ in survival from medulloblastoma?. A study from the SEER registry. J Neurooncol. 2009;95:81-85.
19. Bearer CF. How are children different from adults?. Environ Health Perspect. 1995;103(Suppl 6):7-12.
20. Chang SM, Reynolds SL, Butowski N, et al. GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol. 2005;7:425-434.
21. Chirigos MA, Papademetriou V, Bartocci A, et al. Immune response modifying activity in mice of polyinosinic: Polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC]. Int J Immunopharmacol. 1981;3: 329-337.
22. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
23. Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol. 2011;29:324-329.
24. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer. 2007;110:1542-1550.
25. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11:850-856.
26. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric lowgrade glioma. J Clin Oncol. 2012;30:1358-1363.
27. Fellah S, Girard N, Chinot O, et al. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2011;29:e308-311.
28. Caskey M, Lefebvre F, Filali-Mouhim A, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208:2357-2366.
29. Huang H, Hara A, Homma T, et al. Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol. 2005;64:891-901.
30. Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: A North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009;91:175-182.
31. Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009;91:183-189.
32. Xie X, Zhang D, Zhao B, et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA. 2011;108:6474-6479.
33. Ishii KJ, Kawagoe T, Koyama S, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature. 2008;451:725-729.
34. Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5, ra20.
35. Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17:4790-4798.
36. Myung JK, Cho H, Park CK, et al. Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol. 2012;5:430-436.
37. Weiler M, Wick W. Molecular predictors of outcome in lowgrade glioma. Curr Opin Neurol. 2012;25:767-773.
38. Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci USA. 2013.